Drugs / VX-702
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00395577 | Nov 2006 → Jul 2007 | rheumatoid arthritis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 2 | NCT00205478 | Jun 2005 → Feb 2006 | rheumatoid arthritis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2006-03-08 | Vertex Pharmaceuticals Incorporated | Results Vertex Reports Investigational p38 MAP Kinase Inhibitor, VX-702, Meets Primary Objectives in Phase II Clinical Study in Rheumatoid Arthritis vrtx.com ↗
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that its investigational p38 MAP kinase inhibitor, VX-702, has met its primary objectives in a 12-week Phase II clinical study involving 315 patients. |
| 2004-10-18 | Vertex Pharmaceuticals Incorporated | Results Preliminary Phase IIa Data for VX-702 Demonstrate Tolerability and Reduction in C-Reactive Protein in Cardiovascular Patients vrtx.com ↗
The results, presented at the European Society of Cardiology's Acute Cardiac Care Symposium in Rome, indicate that VX-702 met pre-established safety and pharmacokinetic objectives. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2006-03-08 | Vertex Pharmaceuticals Incorporated | Vertex Reports Investigational p38 MAP Kinase Inhibitor, VX-702, Meets Primary Objectives in Phase II Clinical Study in Rheumatoid Arthritis vrtx.com ↗ |
| 2005-06-10 | Vertex Pharmaceuticals Incorporated | Vertex Pharmaceuticals Initiates Phase II Clinical Study in Rheumatoid Arthritis with Investigational Oral p38 MAP Kinase Inhibitor VX-702 vrtx.com ↗ |
| 2004-10-18 | Vertex Pharmaceuticals Incorporated | Preliminary Phase IIa Data for VX-702 Demonstrate Tolerability and Reduction in C-Reactive Protein in Cardiovascular Patients vrtx.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VX-702 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00205478 ↗ |
| Action | Inhibit | “p38 MAPK inhibition may not provide meaningful, sustained suppression of the chronic inflammation seen in RA.” PMID 19404957 ↗ May 20091“MAP kinase p38 alpha inhibitor” CHEMBL1090090 ↗ |
| Modality | Small molecule | — CHEMBL1090090 ↗ |
| Route | Oral | “Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702” NCT00205478 ↗ |
| Target | MAPK14 | “MAP kinase p38 alpha inhibitor” CHEMBL1090090 ↗ |